Table 2.
Characteristics of the included patients, by country
| Croatia | The Netherlands | UK | |
|---|---|---|---|
| n (%) | 136 (32) | 187 (44) | 100 (24) |
| Median age, years (range)a | 37 (14–68) | 60 (20–89) | 48 (21–74) |
| Sex | |||
| Male | 39 (29) | 91 (49) | 29 (29) |
| Female | 97 (71) | 96 (51) | 69 (69) |
| Other/prefer not to say | 0 (0) | 0 (0) | 2 (2) |
| Education | |||
| Primary education | 3 (2) | 0 (0) | 0 (0) |
| Lower secondary education | 10 (7) | 25 (13) | 4 (4) |
| Upper secondary education | 30 (22) | 29 (16) | 10 (10) |
| Post-secondary but non-tertiary education | 11 (8) | 27 (14) | 5 (5) |
| First stage of tertiary education | 26 (19) | 73 (39) | 42 (42) |
| Second stage of tertiary education | 56 (41) | 33 (18) | 39 (39) |
| Number of prescribed medicines | |||
| 0 | 59 (43) | 6 (3) | 15 (15) |
| 1 | 23 (17) | 16 (9) | 15 (15) |
| 2 | 20 (15) | 20 (11) | 12 (12) |
| 3 | 9 (7) | 9 (5) | 15 (15) |
| 4 | 8 (6) | 27 (14) | 8 (8) |
| 5 or more | 17 (13) | 109 (58) | 35 (35) |
| Experienced an adverse effect | |||
| Yes | 102 (75) | 159 (85) | 80 (80) |
| No | 24 (18) | 23 (12) | 14 (14) |
| Do not know/do not remember | 10 (7) | 5 (3) | 6 (6) |
| Aware of the possibility to report ADRs to the national pharmacovigilance centre | |||
| Yes | 87 (64) | 72 (39) | 69 (69) |
| No | 33 (24) | 55 (29) | 19 (19) |
| I have never heard of the national pharmacovigilance centre | 16 (12) | 60 (32) | 12 (12) |
Data are expressed as n (%) unless otherwise specified
ADR adverse drug reaction
aOne missing from The Netherlands